Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Comps - Mod 3 > Primary 2 - Test 2 - Sheet1 > Flashcards

Primary 2 - Test 2 - Sheet1 Flashcards

1
Q

What meds should be included for a 60 yo male with DM and new diagnosis of CAD. Decreased smoking, walks 2 days/weel x20 minutes, LDL 130, triglycerides 210, non HDL 130, HGB A1c 7%

A

Statin, aspirin, and ACEI

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

A patient returning to the clinic since his first MI should expect to be ordered…

A

Beta blocker

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Post-stent procedure for an MI includes which preferred antiplatelet treatment?

A

ASA and Clopidogrel (Plavix)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Beta blockers and ACEI are used in post-acute MI to…

A

Preserve the contour of the heart

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Characteristics of stable angina include…

A

Occurring with effort

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

The best diagnostic tool to assess for vague complaints of fatigue with walking and possible angina is…

A

Exercise stress test

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Before counseling partners about sexual activity following a MI, the provider should consider what information?

A

Depression, loss of interest, spousal reluctance and anxiety may interfere with a client’s resumption of sexual activities.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Which medication is considered essential in the management of heart failure?

A

ACE inhibitors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What are more common causes of heart failure?

A

HTN, aortic stenosis, and ischemic cardiomyopathy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What is a less frequent cause of heart failure?

A

Valvular heart disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Conditions that result from damages to the heart

A

Angina pectoris and CHF

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Conditions that result from atherosclerosis

A

Peripheral vascular disease adn most CVAs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

The most appropriate coronary heart disease (CHD) recommendations

A

10 Year Risk Estimator for ASCVD

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Determining the risk factor for CHD

A

Can be calculated using age, sex, total and high-density lipoprotein (HDL) cholesterol levels, diagnosis of diabetes, and blood pressure.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Persons at high risk for CHD via the Omnibus Risk Estimator

A

Have greater than 20% 10-year CHD risk, and include persons with established CVD, as well as those with CHD equivalents such as diabetes and chronic renal disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Persons at intermediate risk for CHD via the Omnibus Risk Estimator

A

Have a 10-20% 10-year CHD risk

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Persons at low risk for CHD via the Omnibus Risk Estimator

A

Have less than 10% 10-year CHD risk

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

“Optimal risk” of CHD via Omnibus Risk Estimator

A

Defined as optimal levels of all risk factors and adherence to a heart-healthy lifestyle

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Non-modifiable risks for CHD

A

Gender, ethnicity, age, and genetics.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Homocystein

A

Amino acid occurs naturally in the body. Does not come from diet. Body changes it into another amino acid. Inability to transform to useful acids leads to hyperhomocysteine (15 umol/L to 100 umol/L).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

What causes elevation of homocystein (hyperhomocystein)

A

Genetic defects, smoking, fibrate and niacin meds, and nutritional defects of vitamin cofactors B1, B6, B12

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Hyperhomocysteine

A

Combines with LDL to produce foam cells that form necrotic centers of luminal plaques. Has prothromboic properties - activates protein C, vactors V and VIIA and plasminogen.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

What does hyperhomocysteine impair?

A

Nitric oxide production, free radical oxidation, leukocyte recruitment, and platelet aggregation.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Treatment of hyperhomocysteine levels

A

Folic acid 1 mg/daily can decrease levels up to 72%. Although evidence does not fully support this - no benefit or harm for CVD or CVA

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

C-Reactive Protein

A

Acute phase protein from the liver influenced by cytokines during inflammation responses. Enhances macrophage phagocytosis and complement binding to foreign damaged cells. Does not cause CVD, but shows evidence of CVD. Used for other markers of inflammation.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

C-reactive protein treatment if high

A

Diet, statins, beta blockers, glitazones all can decrease CRP by 50%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

What can increase C-reactive protein?

A

Now evidence that aspirin and hormones are associated with an increase in CRP

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

What has C-reactive protein elevation been correlated with?

A

Future cardiac events (PEACE trial) not a strong correlation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

AHA recommendations for C-reactive protein for patients with low CV risk

A

Low risk = less than 10% in next 10 years. No testing for CRP

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

AHA recommendations for C-reactive protein for patients with intermediate range risks for CV

A

Intermediate = 10-20% in 10 years. CPR can help predict a CV event or stroke and help direct evaluation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

Lipoprotein (a)

A

Modified form of LDL. Similiar to plasminogen which is a protein that helps dissolve clots, so this protein competes with plasminogen and promotes coagulation. Also binds to macrophages that form cholesterol deposition in plaques.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

What is considered high level of lipoprotein (a)?

A

10 mg/dl

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

Who do you test for lipoprotein (a)

A

Those with no identifiable dyslipidemia but established CVD; strong family history of CVD and not other dyslipidemia. HTN with early target organ damage; hypercholesterolemia refractory to therapy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
34
Q

Therapy for lipoprotein (a)

A

NOT diet and exercise and NOT statins. In fact, no treatment approved yet in the U.S. Niaspan has some effect.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
35
Q

Who should be tested for cardiac markers according to the Framingham Score?

A

Yes for everyone.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
36
Q

Framingham Score of <10%

A

No further testing

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
37
Q

Framingham Score of 10-20%

A

Testing is warranted

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
38
Q

Framingham Score of >20%

A

Testing is not warranted because these patients will be treated aggressively

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
39
Q

Presentation of patient with heart failure

A

Shortness of air, edema, and fatigue

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
40
Q

Prevalence of heart failure in U.S.

A

Afflicts 10 out of every 1,000 persons over age of 65

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
41
Q

Percentage of Medicare patients with heart failure who are readmitted within 6 months

A

44%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
42
Q

Burdens of heart failure

A

Congestive symptoms, activity limitation, dysrhythmias, hospitalizations, and reduced survival

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
43
Q

General lifestyle modification measures to treat heart failure

A

Weight reduction, discontinue smoking, avoid alcohol, avoid other cardiotoxic substances, and exercise

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
44
Q

General medical consideration measures to treat heart failure

A

Treat HTN, hyperlipidemia, DM, arrhythmias; coronary revascularization; anticoagulation; immunization; sodium restriction; daily weights; and close out-pt monitoring

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
45
Q

Provider directed or controlled measures to treat heart failure

A

Recognize and treat those at risk for developing heart failure. Maximize survival enhancing medications. Decrease risk of new cardiac injury. Administer influenza vaccine yearly and pneumococcal every 6 yr. Reinforce patient and family involvement in care.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
46
Q

What causes heart failure?

A

The loss of critical quantity of functioning myocardial cells after injury to the heart due to; ischemic heart disease, HTN, idiopathic cardiomyopathy, infections, toxins, valvular disease, and prolonged arrhythmias

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
47
Q

5 year survival rate of persons diagnosed with CHF

A

Less than 50% and less than 25% will be alive in 10 years.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
48
Q

Mortality of older adults with CHF

A

6 year rate of 80% for older men and 65% for older women

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
49
Q

Progression of CHF

A

Incurable and progressive and symptoms can greatly impair functional abilities and quality of life.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
50
Q

Patient management of CHF

A

Requires consultation with a cardiologist

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
51
Q

Therapy for patients under Stage A and Stage B HTN guidelines

A

Treat HTN, hyperlipidemia, etc, dietary salt restriction

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
52
Q

Drugs for routine use for patients under Stage A and Stage B HTN guidelines

A

Diuretics, ACE inhibitors, beta blockers and in some patients- dig, aldosterone inhibitors, ARBs, hydralizine/nitrates

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
53
Q

Symptoms of left ventricular dysfunction

A

Dyspnea on exertion, paroxysmal nocturnal dyspnea, tachycardia, cough, and hemoptysis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
54
Q

Physical signs of left ventricular dysfunction

A

Basilar rales, pulmonary edema, S3 gallop, pleural effusion, and Cheyne-Stokes respirations

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
55
Q

Symptoms of right ventricular failure

A

Abdominal pain, anorexia, nausea, bloating, and swelling

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
56
Q

Physical signs of right ventricular failure

A

Peripheral edema, jugular venous distention, abdominal-jugular reflux, and hepatomegaly

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
57
Q

The Donkey Analogy

A

Ventricular dysfunciton limits a patient’s ability to perform the routine activities of daily living…

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
58
Q

Neurohormonal activation of compensatory mechanisms

A

Many different hormone systems are involved in maintaining normal cardiovascular homeostasis, including: sympathetic nervous system (SNS), renin-angiotensin-aldosterone system (RAAS), and vasopressin (aka antidiuretic hormone, ADH)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
59
Q

Neurohormonal responses to impaired cardiac performance

A

Salt and water retention, vasoconstriction, and sympathetic stimulation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
60
Q

Short-term effects of neurohormonal responses to imapired cardiac performance

A

Augments preload, maintains BP for perfusion of vital organs, and incrases HR and ejection

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
61
Q

Long-term effects of neurohormonal responses to imapired cardiac performance

A

Pulmonary congestion, anasarca, exacerbates pump dysfunction (excessive afterload), increases cardiac energy expenditure, and increases energy expenditure

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
62
Q

Think FACES - symptoms of heart failure

A

F - fatigue; A - activities limited; C - chest congestion; E - edema or ankle swelling; and S - shortness of breath

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
63
Q

Assessing heart failure

A

Consider the patient’s history, physical exam, and lab and diagnostic tests

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
64
Q

Diagnostic evaluation of new onset heart failure

A

Determine the type of cardiac dysfunction (systolic vs diastolic), determine etiology, define prognosis, and guide therapy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
65
Q

Initial work-up of diagnostic evaluation of new onset heart failure

A

ECG, chest x-ray, blood work, ECG

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
66
Q

Class I - New York Heart Association functional classification

A

No symtpoms with ordinary activity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
67
Q

Class II - New York Heart Association functional classification

A

Slight limitation of physical activity. Comfortable at rest, but ordinary physical activity results in fatigue, palpitation, dyspnea, or angina.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
68
Q

Class III - New York Heart Association functional classification

A

Marked limitation of physical activity. Comfortable at rest, but less than ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
69
Q

Class IV - New York Heart Association functional classification

A

Unable to carry out any physical activity without discomfort. Symptoms of cardiac insufficiency may be present even at rest

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
70
Q

Therapies demonstrated to reduce mortality in heart failue

A

ACEI; ARB; BB; aldosterone antagonists; hydralazine-isosorbide dinitrate; ICD (lvef 1120 ms, Class III or IV)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
71
Q

ACE inhibitors - how it saves lives

A

Dilate blood vessels, increase blood flow

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
72
Q

Beta blockers - how it saves lives

A

Help strengthen the herat’s pumping ability, block the response to neurohormonal substances. Slow down the heart rate. Limits the heart’s speed, thus saving energy.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
73
Q

Aldosterone inhibitors - how it saves lives

A

Primarily used in chronic heart failure as a suppressor of the renin-angiotensin-aldosterone system

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
74
Q

Reverse remodeling in HF: Effects of chronic beta-blockage

A

Decreased chamber size (less EDV and ESV), increased LV and RV ejection fractions, improved geometry (restoration of more elliptical shape), and decreased mitral and tricuspid regurgitation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
75
Q

Initial dose of carvidilol (coreg) - BB

A

3.25 bid. CR 10 mg qd

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
76
Q

Target dose of carvidilol (coreg) - BB

A

25-50 mg bid. CR 80 mg qd

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
77
Q

Initial dose of metoprolol XL - BB

A

12.5 md qd.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
78
Q

Target dose of metoprolol XL - BB

A

150 mg/day

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
79
Q

Initial dose of bisoprolol (Zebeta) - BB

A

1.25-2.5

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
80
Q

Target dose of bisoprolol (Zebeta) - BB

A

10 mg qd

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
81
Q

Titration of beta blockers

A

Start low and go slow, double the dose every 2-3 weeks if tolerated. BP >90; HR >60, no signs of decompensation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
82
Q

Diuretics

A

Optimize their effect before and during initiation of other medication treatments

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
83
Q

Diuretics and ACE inhibitors - Donkey analogy

A

Reduce the number of sacks on the wagon

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
84
Q

Captopril dosing (ACEI)

A

Initial 6.25 TID. Max - 50 tid

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
85
Q

Enalapril dosing (ACEI)

A

Initial - 2.5 BID. Max - 10-20 mg BID

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
86
Q

Ramipril dosing (ACEI)

A

Initial - 1.25 - 2.5 mg qd. Max - 10 mg qd. may be given in divided doses

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
87
Q

Quinapril dosing (ACEI)

A

Initial 5 mg bid. Max - 20 mg bid

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
88
Q

Spironolactone dosing (aldosterone antagonists - potassium sparing diuretics)

A

12.5-25 mg daily

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
89
Q

Eplerenone dosing (aldosterone antagonists - potassium sparing diuretics)

A

25 mg - 50 mg daily

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
90
Q

Lab monitoring of aldosterone antagonists - potassium sparing diuretics

A

Serum potassium and creatining should be monitored closely in the first few weeks of therapy. Creatining should be less than or equal to 2.5 mg/dL in men and 2.0 in women and potassium should be less than 5.0

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
91
Q

Aldosterone antagonists - potassium sparing diuretics

A

Used in class II-IV HTN

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
92
Q

Hydralazine and isosorbide dinitrate use

A

Along with ACEI and/or a BB was shown to be significant benefit int he African American cohert

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
93
Q

Dosing of hydralazine/isosorbide

A

37.5/20 tid. Max 2 po tid.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
94
Q

Diuretics

A

Decrease fluid retention and reduce swelling. Improve exercise tolerance. Facilitate use of other drugs for heart failure. Pts can be taught to adjust dose based on symptoms. Electrolyte depletion is frequent. Should never be used alone in heart failure. Higher doses associated with increased mortality. Does not slow the progression of heart failure.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
95
Q

Digoxin

A

Enhances inotropy of cardiac muscles. Reduces activation of SNS and RAAS. Improve circulation by enabling the heart to pump more efficiently. Does not slow the progression of heart failure. Long - term effects - reduces symptoms, increases exercise tolerance, improves hemodynamics, decreases risk of HR progresison, reduces hospitalization, does not improve survival.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
96
Q

Diuretics and heart failure

A

Patients may become unresponsible to high doses of diuretic drugs if they: consume large amounts of sodium, take agents that can block effects of diuretics, have significant impairment of renal funciton or perfusion

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
97
Q

Drugs that block effects of heart failure

A

NSAIDs, COX-2 inhibitors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
98
Q

Diuretic resistance and heart failure

A

Can be overcome by iv administration of diuretics and using 2 or more diuretics in combination

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
99
Q

Digitalis compounds in relation to Donkey Analogy

A

Like the carrot placed in front of the donkey

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
100
Q

Dosing of digoxin

A

0.125 mg - 0.250 mg daily. Increases left ventricular ejection fraction. Should be used in conjunction with other standard therapy that includes ACEI, BB, and diuretics

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
101
Q

Anticoagulants

A

Increased risk due to stasis of blood indilated hypokinetic cardiac chambers and periphery. Risk low in clinically stable. No controlled trials evaluating risk reduction. Justified in those in a-fib or with previous embolic events

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
102
Q

Monitoring for those taking anticoagulants

A

Renal function, electrolytes, CBC, thyroid function, Hgb A1C, ECHO/ECG, and device check

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
103
Q

3 classes of drugs that can exacerbate the syndrome of heart failure and that should be avoided in most patients

A

Antiarrhythmia agents - only amiodarone and dofetilide have been shown not to adversely affect survival. Calcium channel blockers - only the vasoselective ones have been shown not to adversely affect survival. NSAIDs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
104
Q

Potential uses of plasma BNP test

A

Rule out false-positives in CHF. Measure severity of LV compromise. Quantify functional class. Estimate prognosis and predict future cardiac events. Evaluate efficacy of therapy for CHF

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
105
Q

Cardiac resynchroniation therapy - regarding the Donkey Analogy

A

Increase the heart’s efficiency

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
106
Q

Cardiac resynchronization Purpose

A

To improve ventricular synchrony in symptomatic patients

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
107
Q

Cardiac resynchronization - benefits

A

Reverse remodeling, decreased heart size and ventricular volume, improve EF, and decreased mitral regurgitation.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
108
Q

Cardiac rsynchronization - clinical improvements

A

Increase exercise tolerance, quality of life, and rate of hospitalizations

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
109
Q

Cardiac resynchronization therapy - creating realistic patient expectation

A

Approximately two-thirds of patients should experience improvement (responders vs non-responders). Some patients may not experience immediate improvement

110
Q

Having patients set own goals regarding cardiac resynchronization therapy

A

Grocery shopping, decreasing diuretic dose, lying flat to sleep. Encourage them to be part of the group that responds to their therapy

111
Q

ICDs and CRT/ICD

A

Rate of sudden death in a person with heart failure is 6-9x the average person. Those at high risk: EF <30%, ischemic CM, history of SVT, history of SCD

112
Q

A-fib and heart failure

A

Often coexist (10-30%) and significantly effect prognosis as well as complicate management

113
Q

Pharmacological therapies for A-fib

A

Have potentially dangerous side effects.

114
Q

Catheter ablation for A-fib

A

Has been established as an effective therapeutic option and is resistant to pharmacologic rhythm control or rate control

115
Q

Precipitating factors of A-fib

A

Ischemia, sleep apnea, electrolyte abnormality, thyroid disorder, recent myocardial surgery. Is it a rate control vs rhythm control? Consider paroxysmal A-fib and anticoagulation

116
Q

Sleep apnea and heart failure

A

Screen patients for sleep apnea. Ask the following question: Do you snore? Take naps during the day, fall asleep while rising in a car? Feel refreshed upon arising?

117
Q

Important of exercise

A

Encourage pt to perform some form of regular exercise on a daily basis. Increase length of time of exercise. “Start slowly and listen to your body”. Set goals together, ideally, 30 minutes a day 5 days per week.

118
Q

Left ventricular assist devices and Class III and IV CHF

A

Are important in the care and treatment. These devices can provide a bridge to transplant and allow the other organs a change to recover. Heart transplant is another option.

119
Q

Elements of a follow up visit - CHF

A

Assess functional capacity and activity level. Volume status and weight and edema. History of arrhythmia, syncope, palpitation. Careful history of current use of alcohol, tobacco, illicit drugs, sodium intake. Determine understanding of and compliance with medical regime.

120
Q

Patient-contolled measures - CHF

A

Limit daily salt and fluid intake. Eat appropriate diet. Check daily weight. Use flexible diuretic regimen. Improve physical conditioning. Stop smoking. Limit alcohol use. What to do if symptoms worsen. Close follow up and monitoring. Control depression and anxiety

121
Q

Medications known to cause fluid retention

A

Ibuprofen, Cox-2 inhibitors, Actos, Avandia

122
Q

5 and 10 year survival rates with persons diagnosed with CHF

A

50% and 25%

123
Q

6 year mortality of older adults with CHF

A

80% men and 65% women

124
Q

Symptoms of heart failure regarding quality of life

A

It is incurable and progressive and can greatly impair functional abilities

125
Q

Primary care providers regarding CHF

A

Must consult a cardiologist. PCP can provide initial diagnosis, monitoring, and follow-up

126
Q

Acute coronary syndrome

A

Used for the disorders of myocardial ischemia - stable angina, unstable angina, variant angina, or MI

127
Q

ASA for primary prevention requirements for men and women

A

Men at 45 and women at 55 if they have additional CV risk factors AND they aren’t high risk for bleeding. Use 81 mg.

128
Q

ASA for primary prevention requirements for diabetics

A

Save for patients with a 10 year CV risk over 10%. This includes most people if they have risk s like HTN, high lipids, smoke, family hx. Use 81 mg.

129
Q

Indications for a holter monitor

A

Evaluation of frequent, transient symptoms suggestive of a cardiac arrhythmia. Evaluation of chronic arrhythmias (a-fib). ST segment analysis for chest pain. Heart rate variability. Continuous 24 ht heart rhythm monitoring

130
Q

Event cardiac monitor

A

30 day loop recorder. Symptom specific. For infrequent symptoms. Implantable monitor available if symptoms are rare.

131
Q

Goals of stress testing

A

Evaluate exercise capacity. Reproduction of symptoms. HR response- pt with a-rib. Arrhythmias. Comparison to previous studies. Evaluate for MI.

132
Q

Exercise ECG

A

Usually treadmill. Usually maximal unit individual cannot exercise any longer or until certain endpoints develop (chest pain, target heart rate reached, arrhythmias, ECG changes). Abnormality usually based on ECG criteria.

133
Q

Sensitivity of stress ECG for detecting single and three vessel disease

A

Single - 50%. Three vessel - 85%

134
Q

Exercise ECG advantages

A

Relatively inexpensive. WIdely available. Straightforward interpretation. Can be scheduled quickly.

135
Q

Exercise ECG disadvantages

A

Moderate sensitivity and specificity. Requires a certain amount of effort and a target HR needs to be achieved. Higher false positives in women, pts with mitral valve prolapse, resting ECG abnormalities such as LBBB or in the setting of certain drugs (Digoxin)

136
Q

Stress echo imagine

A

With exercise stress or pharmacologic stress, there is increasing O2 demand by the myocardium. In the setting of significant coronary artery narrowing, the O2 demand exceeds the blood supply and results in a stress related wall motion abnormality.

137
Q

Transthoracic and transesophageal ECHO

A

Transthoracic - standard approach with 4 views of left ventricular cavity. Transesophageal - can be used with pharmacologic stress or with pacemaker

138
Q

Stress ECHO in detecting single and three vessel disease

A

Single - 58%. Three vessel - 94%

139
Q

Stress ECHO advantages

A

Portable. Less expensive. No radiation exposure. Provides cardiac structural info in addition to perfusion information

140
Q

Stress ECHO disadvantages

A

Not able to image in all patients (large chest and COPD). Results are not as reproducible and prognostic info is just being developed. Difficult to interpret in setting of previous MI with resting wall motion abnormalities.

141
Q

Nuclear stress test advantages

A

Reproducible. Able to obtain images in all patients regardless of size. Exercise or pharmacological. Extensive data supporting reliability of results and prognostic info.

142
Q

Nuclear stress test disadvantages

A

Expensive. Requires expensive, sophisticated equipment in fixed location. Requires strict adherence to standards related to radioisotope handling. Radiation exposure.

143
Q

Limitations to exercise stress testing

A

PVD. Arthritis/orthopedic. COPD. Extremity amputation. Poor exercise capacity. Beta blocker use (limits heart rate response). Neurologic. Systemic muscular disease.

144
Q

Pharmacologic stress agents

A

Primary (direct) vasodilators - Adenosine and persantine. Secondary (indirect) vasodilators - dobutamine

145
Q

Careful use of dobutamine stress - inotropic

A

Must be combined with imaging. Can trigger arrhythmias due to catecholamine surge. May be an unsettling sensation for many patients. If HR response is suboptimal, atropine may be given IV.

146
Q

Side effects of dobutamine

A

HA, nausea, palpittions, flushing, arrhythmias, and chest pain.

147
Q

Adenosine stress test

A

Potent receptor-mediated vasodilator. Increases coronary blood flow 3-5x normal. Short biological half-life (10 seconds). Causes mismatch of perfusion in areas of significant coronary stenosis. Needs accompanying nuclear perfusion. Avoid in pts with significant lung disease as this can trigger bronchospasm.

148
Q

Side effects of adenosine

A

HA, flushing, chest pain, nausea, dyspnea, lightheadedness, AV block, high degree AV block in <2%. Severe bronchospasm. Chest pain 90% - non-specific.

149
Q

Stress testing with left bundle branch block

A

Frequent “false-positive” exercise studies due to effectson ST/T wave segments. Cannot accurately distinguish coronary artery disease from LBBB artifact. Adenosine stress is study of choice!

150
Q

Stress testing and caffeine

A

Must be off all forms of caffeine for 24 hrs

151
Q

Stress testing and patients with paced rhythms

A

Frequent “false-positive” exercise studies due to reversible or partially reversible distal septal/inferoapical defects. Cannot accurately distinguish CAD from PM artifact although frequentlydo not fit standard anatomic distributions. Adenosine stress is study of choice!

152
Q

Left ventricular hypertrophy with strain and stress testing

A

May also cause false positive exercise stress test results related to abnormal ST depression seen with “strain” pattern on the ECG. Adenosine is the study of choice. If interested in exercise capacity, must add nuclear images to exercise test.

153
Q

2D echo with doppler

A

Evaluation of heart function: chamber size and contracility. Evaluation of valves and blood flow. Clinical applications - valvular disease, congenital heart disease, myocardial disease, pericardial disease

154
Q

MUGA - multiple gated acquisition scan

A

Can test for right and left ventricular ejection fractions.

155
Q

PET myocardial view

A

Current “Gold Standard” for viability. Positional Emission Tomography (PET) is a specialized nuclear imaging technique to assess myocardial perfusion and viability. Differentiates between ischemic tissue and scarred tissue.

156
Q

Cardiac MRI

A

Limitations include lack of portability, no permanent pacemakers, no AICDs, high cost

157
Q

Venous and arterial duplex (Doppler Ultrasound)

A

Duplex refers to 2 modalities: images and velocity. Used to assess carotids with cerebrovascular symptoms. Primary tool to diagnose DVT.

158
Q

What to ask chest complaints to differentiate those with ACS

A

Where, when did it start, how long, what aggravates, what alleviates, does it radiate, associated symptoms, has it ever happened before? If you think it is ACS, then jump into action!

159
Q

Patients with unstable angina

A

Should be transported via EMS to a hospital for eval. Give 165 - 325 mg non-enteric coated ASA to all pts. Give O2 and subling nitro and morphine maybe.

160
Q

ASA and prophylaxis

A

Consider for all pts with increased risk for CHD.

161
Q

All patients with CAD should be taking the following meds unless contraindicated

A

Aspirin, a lipid lowering agent if LDL above target, and a beta-blocker. Long acting calcium channel blockers are useful adjuncts if patients with contraindications to beta blockers.

162
Q

Types of calcium channel blockers

A

Dihydropyridines or nondihydropyridines

163
Q

Med names of dihydropyridines

A

Amlodipine, felodipine, and nifedipine. Expensive

164
Q

Med names of nondihydropyridines

A

Dilitiazem and verapamil

165
Q

Calcium channel blocker effects

A

Inotrpic effects - all relax arterial smooth muscle and produce peripheral vasodilation that lowers BP. Affect cardiac contraction by calcium channel blockge and depress cardiac contractility

166
Q

Negative inotropic effect of calcium channel blockers

A

The negative effect of depressing cardiac contractility isnot with the dihydropyridines because they are more potent vasodilators. This leads to baroreceptor mediated increase in sympathetic tone and blunts the negative effect. Best used if needed in HF.

167
Q

CAD is a spectrum

A

Pts move along the spectrum from stable to unstable angina to NSTEMI to STEMI, to HF. Providers need to know where on the spectrum the patient is currently, and work to treat current stage and prevent progression. Once on the spectrum, treatment is secondary prevention!

168
Q

Meds post-MI

A

High intensity cholesterol, ACE, ASA, plavix, beta blocker and nitro

169
Q

Drug eluting cardiac stents

A

Have been associated with fewer restenosis (due to overgrowth of smooth muscle cells that block the stent) events initially but may have more late stent thrombosis at the 3 year mark

170
Q

FNP care post-MI

A

Make sure pt is on ASA and plavix, usually for 1 year for both after MI. After 1 year, plavix can be discontinued and stay on ASA.

171
Q

Use of plavix

A

Even though expensive, it is like a super aspirin. Acts on adenosine phosphate receptor on the platelet cell membrane, which inhibits the activation of platelets.

172
Q

How aspirin work

A

Works on the aggregation of platelets.

173
Q

When can patients typically return to work after MI

A

Typically when they can walk up a flight of stairs without being out of breath. No set guidelines.

174
Q

Healing time of cardiac tissue and stent placements

A

4-6 weeks and usually 1 month

175
Q

Adverse effect of Norvasc

A

Doesn’t have negative ionotrophic effect, but is notorious for causing peripheral edema

176
Q

Meds for patient with heart failure

A

Diuretics - HCTZ then loop. ACE-I - lisinopril. Beta blocker - metoprolol do not stop abruptly. Aldosterone antagonist - only mod-severe to severe symptoms. Na+ restrictions. Lipids - new guidelines. Daily exercise. Avoid NSAIDS. Prevention - flu and pneumonia vaccine. Education. At every visit assess functional status and recent clinical visits.

177
Q

Why use diuretics

A

Reduce symptoms more rapidly than any other class of meds. Critical for maintenance of Na+ balance. Goal is to increase urinary output and decrease clinical evidence of fluid retention. Weight loss will be about 0.5-1.0 ky/day. Loop diuretics preferred.

178
Q

Why use ACEs

A

Inhibit RAA system, and modify LV remodeling. If intolerant, use ARB

179
Q

Why use BBs

A

Inhibit SNS effect on CV system. Only three approved for HF. Monitor for early fluid retention d/t negative inotropic effect.

180
Q

Length of time to achieve maximum effects of beta blockers adn ACEIs

A

May take weks to months

181
Q

Why use aldosterone antagonists

A

May have negative effects on structure & function of heart. Require close monitoring of potassium and renal status especially in insulin-dependent DM. Contraindications - elevated creatinine, hyperkalemia, other potassium sparing diuretics. Monitor at 1 day 1 week and 1 month

182
Q

Why use digoxin

A

May improve exercise tolerance, quality of life & symptoms. May be added if on diuretic, ACE-I, and BBs

183
Q

Chronic stable angina

A

Precipitated by exertion and relieved at rest. Symptoms occur with predictable frequency, severity, duration, and provocation and generally last 1-3 minutes.

184
Q

Variant angina

A

History of spontaneous or unprovoked episodes of typical angina. Occurs predominantly at rest and is usually not provoked by exertion.

185
Q

Side effects of beta blockers

A

Fatigue, impotence, cold extremities, bronchospasm, worsening claudication, bradycardia, and cardiac conduction disturbances.

186
Q

Effects of abrupt discontinuation of beta blockers

A

May precipitate angina symptoms or lead to MI as a result of rebound tachycardia.

187
Q

Most common cause of systolic heart failure

A

Coronary artery disease

188
Q

Common causes of diastolic heart failure

A

HTN, A-fib, and diabetes

189
Q

Cardinal symptoms of heart failure

A

Dyspnea and fatigue

190
Q

Diagnostic exam of heart failure

A

Echo

191
Q

Standard first-line approach to initial testing for CAD

A

Exercise tolerance test

192
Q

Venous stasis ulcer

A

An ulcer that has an irregular border with a red base often with redden, swollen shiny appearing skin located on the medial side of the leg

193
Q

If an ultrasound indicates an aortic aneurysm of 3 cm in diameter, what is your next step

A

Monitor with ultrasound every 2-3 years

194
Q

What is the best initial plan for a 60 year old male diagnosed with mild arterial insufficiency

A

Encourage walking to the point of pain as often as possible

195
Q

Instructions to provide to a patient diagnosed with severe arterial insuffiency

A

Toenail trimming should be done by the podiatrist, comfortable tennis shoes are fine as long as they fit properly, and it is best to examine feet for lesions rather than relying on being able to feel pain.

196
Q

Raynaud’s phenomenon

A

A condition in which cold induces vasospasm of the small blood vessels in the fingers and toes causing a characteristic blanching

197
Q

What would you counsel for a patient diagnosed with ischemic arterial ulcers

A

Reduce risk factors such as stopping smoking and reducing fat intake, avoiding restrictive garments and trauma, and maintaining adequate hydration but avoiding drinks containing caffeine

198
Q

An Unna boot is appropriate for….

A

Venous stasis ulcers

199
Q

Chronic warfarin therapy for anticoagulation should include maintaining the INR between

A

2.0-3.0

200
Q

Does a CHADS2 score of 1 require coumadin therapy?

A

No

201
Q

Would routine screening for peripheral vascular disease be part of a work-up?

A

No, there is no data to support this as beneficial in terms of mortality or morbidity reduction

202
Q

In a patient without symptoms to suggest PVD, what PVD primary prevention would be included in patient education

A

Smoking cessation

203
Q

Differential diagnoses for a patient who complains of pain in legs when walking includes

A

Cauda equina, acute embolism, and DVT

204
Q

The most reliable physical finding in patients with PVD includes

A

Presence of femoral artery bruit

205
Q

Management of PVD includes

A

Montoring symptoms because patients with claudication may progress to acute or critical limb ischemia, monitoring degree of pain and pain free walking, and treatment with ASA and exercise to decrease risk of serious vascular events and increased walking time.

206
Q

Arteriosclerosis obliterans (ASO)

A

Used to indicate lesions of the aorta, its proximal branches, and the arteries of the legs

207
Q

Risk factors of chronic arterial insufficiency and aortic aneurysms

A

Result from arteriosclerosis and have same risk factors of other atherosclerotic conditions. Almost always signal the presence of disease in the coronary and cerebral vasculature as well.

208
Q

Symptoms of PAD

A

Calf muscles that shrink (late sign), hair loss over toes and feet (late signs), thick toenales, shiny tight skin, painful non-bleeding ulcers on feet or toes that are slow to heal, and an early sign might be that legs hurt or become tired when walking far.

209
Q

Intermittent claudication

A

More than twice as common in men earlier in life and is like angina to the leg muscles

210
Q

Ischemic leg pain at rest

A

O2 to the foot is so insufficient that the patient may experience tissue necrosis spontaneously or from minor trauma. Needs to be referred to vascular surgeon urgently.

211
Q

Other causes of lower leg pain

A

Joint dysfunction, peripheral neuropathy, spinal stenosis, and lumbar disc disease and must be ruled out in H&P

212
Q

Treatments for patients with intermittent claudication

A

Balloon angioplasty, rotary atherectomy, stent placement, or bypass surgery. Usually reserved for patients who have failed at exercise and patients with co-morbidities (MI, CVA, DM)

213
Q

PAD

A

May be the first sign of cardiovascular disease. Caused by smoking, diabetes, and obesity. Affects African-Americans more common.

214
Q

What causes PAD

A

Atherosclerosis: when the wall of the artery thickens because there is a build-up of fatty material (plaque) such as cholesterol

215
Q

Who is at risk for PAD

A

Older (over 50), smoking, diabetes, HTN, high cholesterol, overweight

216
Q

Symptoms of PAD

A

Many have no symptoms, pain in legs while walking, pain in foot while at rest (Severe symptoms), and ulcers that fail to heal or Gangrene

217
Q

ABI procedures to test for PAD

A

Blood pressure in arm and ankle using a doppler should be equal. Anything less than 90% indicates a problem with circulation.

218
Q

Exercise ABI testing for PAD

A

Used when the ABI is normal or borderling but symptoms are consistent with claudication. A drop in ABI post-exercise supports a PAD diagnosis

219
Q

Prognosis of PAD

A

Increased risk of for cardiovascular disease. Severity is linked to risk. Those without symptoms have low risk of amputation. Overall 20-30% may require a surgical procedure within 5 years to increase blood flow. Severe disease requires prompt attention and treatment.

220
Q

Key Features of PAD-related leg pain

A

Cramping, aching, tightness, fatigue; calf, thigh or buttock muscles; exercise-dependent; consistently brought on by exercise to similiar degree or walking distance; not brought on by simple standing or changes in position; and quickly relieved by rest (standing still)

221
Q

Critical limb ischemia (CLI) - more severe PAD

A

Advanced state with severe reductions in blood flow; high risk for amputation if untreated; pain in feet or toes at rest, often at night, relieved by dangling; advanced signs such as discoloration or open sores develop; limb salvage requires procedures to improve blood flow to the foot

222
Q

Goals of treatment of PAD

A

Improve limb outcomes and reducing cardiovacular events - decrease morbility and mortality from MI and stroke

223
Q

General treatment of PAD

A

Risk factor management - stop smoking, diet and lifestyle changes, and glucose control. Medications to reduce CV events - ASA and plavic, statins and cholesterol lowering drugs, and HTN meds

224
Q

Treatment of leg of PAD

A

Exercise - supervised programs. Meds - pletaal may improve walking in some patients. Most pts with mild disease do not require surgerical procedures. Pts with advanced disease may benefit from procedures to open or bypass. See a dedicated vascular specialist.

225
Q

Diabetes and PAD

A

Increased risk of amputation, nerve damage and impaired resistance to infection contribute to foot problems, careful attention to preventive foot care, and close monitoring by a vascular specialist - minor foot problems can rapidly worsen and Gangrene much more likely

226
Q

A-fib

A

Most common heart rhythm abnormality and is characterized by an irregularly irregular heartbeat.

227
Q

Great danger of A-fib

A

Blood clots can develop within the quivering left atrium and be prepared into general circulation with some reaching the brain

228
Q

Drugs used to convert A-fib into a normal rhythm

A

Calcium channel blockers - diltiazem and verapamil; small dosease of beta blockers; and less common digoxin.

229
Q

Coagulation therapy and A-fib

A

Until normal rhythm is restored, anticoagulation therapy is required. Coumadin is more effect than ASA and can be used together

230
Q

Coumadin use and A-fib

A

Not every patient receives coumadin. Now use the CHAD2 scoring system to decide on risk for stroke.

231
Q

Major risks for abdominal aortic aneurysm

A

Age >65, male, history of smoking at least 100 cigarettes in a person’s lifetime, first-degree family history of AAA requiring surgical repair elevates a man’s risk but not as clear for women, modest association between risk factors for atherosclerotic disease and AAA

232
Q

Description of AAA

A

“Searing pain in my belly that goes right through to my back”

233
Q

Screening recommendations by the USPTSF

A

One-time screening using ultrasound in men aged 65-75 whi have ever smoked, no recommendation for men who have never smoked, and women should not be screened

234
Q

AAA pathophysiology

A

Arises as a consequence of loss of structural integrity leading to dilation of the abdominal aortia

235
Q

Occurrance of AAA

A

More common in men, 6% men older than 65 years, higher in whites

236
Q

Risk factors for AAA

A

Atherosclerotic vascular disease, white race, male gender, advanced age, HTN, smoking, COPD, history of hernias, family history of AAA, and presence of other aneurysms

237
Q

Clinical presentation of AAA

A

Results from pressure to surrounding structures and 75% are asymptomatic. May see a pulsatile abdominal mass. May see abdominal pain, back pain. “Shearing pain”

238
Q

Detecting AAA in older men

A

Palpation is one of the few exams that is EBP

239
Q

Diagnostic test for AAA

A

Ultrasound

240
Q

Differential diagnoses of AAA

A

MI, esophageal rupture, perforated gastric ulcer, pancreatitis, bowel obstruction, appendicitis, ischemic bowel, back strain, and arthritis

241
Q

Management of AAA

A

Prevent aneurysmal rupture while minimizing surgical risk

242
Q

Factors that dictate elective AAA repair

A

Size of aneurysm, patient’s medical status, life expectancy

243
Q

Best predictor of AAA rupture

A

Size of aneurysm, patient’s medical status, life expectancy

244
Q

When to refer a AAA

A

When 4.0 cm or larger to a vascular surgeon. Elective repair - 5.0-6.0 cm. Expansion beyond 10% of diameter per year.

245
Q

Most common symptom of arrhythmias

A

Palpitations

246
Q

Palpitations in A-fib

A

Usually irregular and may be more sustained

247
Q

Physical exam of patient with arrhythmia

A

General appearance, particularly color, diaphoresis, respiratory effort, and anxiety, hydration status, vital signs, and mental status

248
Q

A-fib on ECG

A

Normal P wave is replaced by fibrillatory F waves, producing a wavy baseline. Rate estimated between 350-650 beats/min.

249
Q

Therapeutic goals or treatment of A-fib

A

Control rate and prevention of thromboembolisms.

250
Q

Common causes of A-fib

A

Rheumatic heart disease, mitral valve disease, HTN, CAD, hyperthyroidism, stimulant ingestion, ETOH withdrawal, and acute pulmonary disease

251
Q

Therapeutic procedure to correct a-fib

A

Cardioversion; sotalol; digoxin - not used as commonly; ETT

252
Q

Meds to control A-fib

A

Sotalol; digoxin; beta blockers; calcium channel blockers; amiodarone; anticoagulation therapy

253
Q

Anticoagulation therapy for A-fib in low-risk patients

A

Those younger than 60 without heart disease may use ASA or a combo of ASA and plavix for those who can not take warfarin

254
Q

Anticoagulation therapy for A-fib in most patients

A

Warfarin is preferred

255
Q

CHADS2 score

A

Used to calculate embolic risk on the basis of a patient’s other comorbid factors

256
Q

Arrhythmias that require hospitalization

A

Any that produces hemodynamic decompensation

257
Q

Referral for arrhythmias

A

When treatment requires a nonpharmacological agent, such as a pacemaker, catheter ablation, or ICD implant

258
Q

Peripheral arterial insufficiency

A

Condition that results when there is insufficient blood flow to the extremities. More common in lower extremities.

259
Q

Pathyphysiology of chronic arteial insufficiency

A

Results from diverse systemic conditions that affect arteries found in different parts of the circulatory system, even in the absence of clinical symptoms.

260
Q

Classic symptom of peripheral arterial insufficiency

A

Claudication

261
Q

Claudication

A

Tightening or cramping pain usually in the calf muscles that is precipitated by exercise and is relieved by rest

262
Q

Iliac artery obstruction (Leriche’s syndrome)

A

Claudication that begins typically while in bed and is relieved by dangling the legs over the side of the bed

263
Q

Physical characteristics of peripheral artery insufficiency

A

Muscle wasting, loss of hair, and reduced temp in affected limb, absence of pulses, dependent rubor

264
Q

ABI (Ankle-brachial index)

A

Most useful tool in assessing peripheral arterial insufficiency

265
Q

Differential diagnoses of peripheral insufficiency

A

Peripheral neuropathy, cauda equina syndrome, Buerger’s disease, leg cramps, and musculoskeletal disorders

266
Q

Cauda Equina Syndrome

A

Spinal stenosis causing pressure on the nerve roots may result in symptoms of claudication from the hip downward, which can be confused with Leriche’s syndrome. Often must rest longer to relieve symptoms.

267
Q

Buerger’s disease

A

Inflammatory occlusive disease of medium and smaller arteries of arms and legs, very common among smokers.

268
Q

Referring patients with peripheral artery insufficiency

A

When severe claudication results, rest pain, or gangrene

269
Q

Acute arterial insufficiency

A

The sudden onset of the symptoms of ischemia and usually the result of an embolus

270
Q

Clinical presentation of acute arterial insufficiency

A

Usually with a history of sudden onset of pain in an extremity.

271
Q

Physical exam of acute arterial insufficiency

A

Usually limb is pale and pulseless with absent or diminished cap refill, loss of sensation or immobility. Become gangrenous if untreated.

272
Q

Management of venous stasis ulcers

A

Bed rest. Wet-to-dry dressings after debridement. antibiotics. Nonstick dressings may be less painful.

Comps - Mod 3 (5 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions